About G2/mitotic-specific cyclin-B2
G2/mitotic-specific cyclin-B2 (CCNB2) is a protein
from Homo sapiens identified by UniProt accession
O95067, 398 residues long.
MolForge cross-references it against 0 known binders and
164 disease associations.
Target properties
| Protein name | G2/mitotic-specific cyclin-B2 |
|---|
| UniProt accession | O95067 |
|---|
| Gene | CCNB2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 398 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (164)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.28
- endometrial cancer · score 0.25
- esophageal cancer · score 0.23
- low density lipoprotein particle size measurement · score 0.21
- squamous cell lung carcinoma · score 0.19
- hepatocellular carcinoma · score 0.12
- body fat percentage · score 0.11
- lean body mass · score 0.10
- neoplasm · score 0.09
- fat body mass · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95067-F1 | alphafold | PREDICTED | 79.36 | — |
Amino-acid sequence (398 residues)
MALLRRPTVS SDLENIDTGV NSKVKSHVTI RRTVLEEIGN RVTTRAAQVA KKAQNTKVPV QPTKTTNVNK QLKPTASVKP VQMEKLAPKG PSPTPEDVSM KEENLCQAFS DALLCKIEDI DNEDWENPQL CSDYVKDIYQ YLRQLEVLQS INPHFLDGRD INGRMRAILV DWLVQVHSKF RLLQETLYMC VGIMDRFLQV QPVSRKKLQL VGITALLLAS KYEEMFSPNI EDFVYITDNA YTSSQIREME TLILKELKFE LGRPLPLHFL RRASKAGEVD VEQHTLAKYL MELTLIDYDM VHYHPSKVAA AASCLSQKVL GQGKWNLKQQ YYTGYTENEV LEVMQHMAKN VVKVNENLTK FIAIKNKYAS SKLLKISMIP QLNSKAVKDL ASPLIGRS
Explore G2/mitotic-specific cyclin-B2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets